Hydroxychloroquine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Hydroxychloroquine
Hydroxychloroquine: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Hydroxychloroquine, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 11 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| chronic cutaneous lupus erythematosus |
| discoid lupus erythematosus |
| lupus erythematosus |
| malaria |
| pediatric systemic lupus erythematosus |
| plasmodium falciparum malaria |
| plasmodium malariae malaria |
| plasmodium ovale malaria |
| plasmodium vivax malaria |
| rheumatoid arthritis |
| systemic lupus erythematosus |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 1512N | Hequinel | Tablet containing hydroxychloroquine sul | Valid |
Safety Considerations
Detailed label warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
- Conditions flagged in the knowledge graph as contraindications or cautions: porphyria (including inherited forms), liver and gallbladder disease, eye disease including retinal disease, retinitis, scotoma, vision disorders and blindness, psoriasis, neutropenia, agranulocytosis, anaemia, G6PD deficiency, substance abuse or dependence, glycogen storage disease, cystinuria and galactosemia. These come from knowledge graph relationships, not label text, and need confirmation against the PI.
- Drug interactions: 100 interactions were identified. The sample reviewed included:
- Major: clarithromycin, dolasetron, palonosetron.
- Moderate: famotidine, cimetidine, loperamide, aprepitant, bisacodyl, metronidazole, and the glucose-lowering agents chlorpropamide, glimepiride and several insulins (hypoglycaemia risk is a particular concern).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.